202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor

J Wang,Y Shen,J Chen,X Chen,Q Guan,Q Liu,J Xu,Y Xu,B Zhang,H Zhang,Y Zhu,Y Zhang

doi:10.1016/j.annonc.2022.10.238

202TiP A single-arm, open, multicenter and exploratory clinical study of fluzopari combined with apatinib in pts with platinum-sensitive relapsed ovarian cancer first-line treated with a PARP inhibitor

J Wang, Y Shen + Show 10 more

Open Access

https://doi.org/10.1016/j.annonc.2022.10.238

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Nov 1, 2022
License type: publisher-specific-oa

Affiliation: Jiangsu Cancer Hospital, Nanjing Medical University, Nanjing Maternity and Child Health Care Hospital

#Platinum-sensitive Recurrent Ovarian Cancer #PARP Inhibitors + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

PARP inhibitors (PARPi) have been approved as maintenance therapy for patients with platinum-sensitve recurrent ovarian cancer. Fluzoparib, a novel, potent and orally available PARPi, significantly inhibited PARP1 activity. It had promising antitumor activity in patients with maintenance therapy and platinum-sensitive recurrent ovarian cancer with germline BRCA1/2 mutations who had received previous 2-4 lines of chemotherapy. However, the treatment consensus after PARPi has not been established.

Full Text